Fig. 4
From: CAR-T cells targeting CD38 and LMP1 exhibit robust antitumour activity against NK/T cell lymphoma
Effectiveness of CAR-T cells on NKTCL in vivo. a Overview of the treatment of xenograft tumour model in vivo. b, c Tumour growth was monitored by IVIS living imaging. The mouse tumour burden was indicated by bioluminescence radiance. d Tan CAR-T cells showed a significant anti-tumour effect compared to CD38- or LMP1-CAR-T cells. e IHC showed that tumours isolated from mice were positive for CD3ε, CD56 and EBER. Arrows showed the positive cells. Scale bar: 10 μm. A value of p < 0.05 was considered statistically significant. ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001